Feature | Coronavirus (COVID-19) | April 13, 2021| By Dave Fornell, Editor

CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots

AstraZeneca vaccine clotting complications similar to Janssen reports and both use a similar viral delivery vector

CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen

(This story was updated May 7, 2021 in the last subheaded section)

April 13, 2021 — The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are calling for a pause in using the Johnson & Johnson/Janssen COVID-19 (SARS-CoV-2) vaccine today after several reports of a rare, severe, stroke-like type of blood clot in patients after receiving the J&J vaccine. One patient has died from the complication and one remains in critical condition.

In a joint statement from the CDC and FDA, they said there were six cases cerebral venous sinus thrombosis (CVST) blood clots seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, the anticoagulant heparin is used to treat blood clots, but in this setting, administration of heparin can be dangerous and alternative treatments need to be given.

CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday, April 14, to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. 

"Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution," said Peter Marks M.D., Ph.D., director of the FDA Center for Biologics Evaluation and Research (CBER). "This is important, in part, to ensure that the healthcare provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot."

He said right now, these adverse events appear to be extremely rare. However, Marks explained COVID-19 vaccine safety is a top priority for the federal government.

"We take all reports of adverse events following vaccination very seriously," Marks said. "Healthcare providers who see people presenting to them with either a low platelet count or blood clots should establish whether or not the individual has been recently vaccinated in order to inform the proper diagnostic evaluation and management."

Healthcare providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.html.

The CDC and FDA held a press briefing today and a recording will be available on the FDA’s YouTube channel.

Janssen Vaccine Appears to be Safe in Vast Majority of Patients

Overall, the experts say the Janssen vaccine is very safe, with only 6 known cases of this severe adverse event out nearly 7 million doses of the Janssen vaccine administered so far. 

"Right now these events appear to be extremely rare," Marks said in the press conference. "Healthcare providers who see people who are presenting with blood clots and have low blood platelets should assess if the patient has received a COVID vaccine."

As of April 12, the FDA said more than 6.8 million doses of the Janssen vaccine have been administered in the U.S.  The FDA issued an emergency use authorization (EUA) for the Janssen Biotech COVID-19 Vaccine, the third vaccine for the prevention of coronavirus, Feb. 27. It is available for use in the U.S for use in individuals 18 years of age and older. 

Healthcare Workers Need to Recognize CVST and Low Platelets as Possible Side Effect of Janssen Vaccine

However, there are concerns that there could be more cases of CVST blood clots seen in combination with thrombocytopenia that might not have been connected yet to the vaccine, or patients may still present to hospitals or their primary physician with symptoms up to three week after getting the Janssen vaccine. Marks said the pause is in part to make sure all healthcare providers are aware this can be an issue and to be alert if a patient presents with clots and low platelets and not to treat them with heparin and recognize this might be related to a vaccine.

"We know the information we are providing today will be very concerning to many people who already received the Johnson and Johnson vaccine," explained Janet Woodcock, M.D., acting FDA commissioner. "We are recommending this pause in order to prepare the healthcare system to recognize and treat these patients appropriately and to report severe events they may be seeing in people who received the J&J vaccine."

What are the symptoms and When Should Patients Go to the Hospital if They Had The Janssen Vaccine?

If patients have very severe headaches, or pain in their legs or abdomen, it could be a sign on clot formation and they should seek medical evaluation, Marks said.

"People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their healthcare provider," he said.

However, he added that mild headaches and flu-like symptoms are common with the vaccines and should not cause for alarm. Marks said these symptoms usually go ways after a day or two. 

Clotting Complications Due to AstraZeneca Vaccine Similar to Janssen 

The AstraZeneca COVID vaccine (also known as Vaxzevria and the AstraZeneca-Oxford vaccine) was approved for use in Europe has recently come under fire because of a number of adverse event reports involving clotting. As of April 4, the New York Times reported European regulators had received reports of 222 cases of the rare blood-clotting problem across Europe, including 18 deaths. They said that about 34 million people had received the AstraZeneca vaccine in those countries, and that the clotting problems were appearing at a rate of about one in 100,000 recipients. That is much higher than the rate currently found for the Janssen vaccine.

It is believed the AstraZeneca vaccine recipients who developed the clotting disorder produced antibodies that activated their platelets and led to the clots. Marks said this appears to be the same process in the U.S. cases with the Janssen vaccine. 

"What we are seeing with the Janssen vaccine is very similar to the AstraZeneca vaccine, and that makes sense because they use a similar vector," Marks explained. "AstraZeneca uses a chimpanzee adenovirus vector, and the Janssen vaccine uses a human adenovirus vector."

Adenoviruses cause the common cold and can be rendered harmless for use in vaccine production to deliver a piece of genetic code from a pathogen to cells in the body that mimic an infection, in this case by replicating the COVID spike protein. The harmless virus acts as a delivery system, or vector, for the genetic sequence and the body's immune system reacts to it and creates antibodies to fight it without actually being exposed to the real virus.

Read more about viral vector vaccaines on the CDC website

Woodcock said more than 180 million doses of COVID vaccine have been delivered so far in the U.S., Marks said. Of these doses, the vast majority have been the Pfizer and Moderna vaccines, which use an mRNA vector and have zero reported complications of this type.

 

Agencies Underscore Confidence in Janssen Vaccine Safety and Effectiveness Following Data Assessment and Potential Blood Clots Are Very Rare Events

On April 23, the FDA and Centers for Disease Control and Prevention (CDC) announced lifting the pause on the use of Janssen (Johnson & Johnson) COVID-19 Vaccine. This followed a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

The agencies confirmed that a total of 15 cases of TTS have now been reported to VAERS, including the original six reported cases. All of these cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Reports indicated symptom onset between 6 and 15 days after vaccination. 

The pause was recommended after reports of six cases of a rare and severe type of blood clot in individuals following administration of the Janssen COVID-19 Vaccine. During the pause, medical and scientific teams at the FDA and CDC examined available data to assess the risk of thrombosis involving the cerebral venous sinuses, or CVST (large blood vessels in the brain), and other sites in the body (including but not limited to the large blood vessels of the abdomen and the veins of the legs) along with thrombocytopenia, or low blood platelet counts. The teams at FDA and CDC also conducted extensive outreach to providers and clinicians to ensure they were made aware of the potential for these adverse events and could properly manage and recognize these events due to the unique treatment required for these blood clots and low platelets, also known as thrombosis-thrombocytopenia syndrome (TTS).

The two agencies have determined the following:

   • Use of the Janssen COVID-19 Vaccine should be resumed in the United States. 

   • The FDA and CDC have confidence that this vaccine is safe and effective in preventing COVID-19.

   • The FDA has determined that the available data show that the vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years of age and older.

   • At this time, the available data suggest that the chance of TTS occurring is very low, but the FDA and CDC will remain vigilant in continuing to investigate this risk.
   
   • Healthcare providers administering the vaccine and vaccine recipients or caregivers should review the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Fact Sheet for Recipients and Caregivers, which have been revised to include information about the risk of this syndrome, which has occurred in a very small number of people who have received the Janssen COVID-19 Vaccine.

 

Related COVID Vaccine Content:

FDA Clears Third COVID-19 Vaccine From Janssen

VIDEO: COVID Vaccine May Cause Enlarged Lymph Nodes on Mammograms

COVID-19 Vaccine Can Cause False Positive Cancer Diagnosis

FDA Clears First COVID-19 Vaccine Under an Emergency Use Authorization

FDA Approved Second COVID-19 Vaccine From Moderna

COVID-19 Patients With Cardiovascular Disease Have In-hospital Mortality Rates of 25 to 38 Percent

Who Qualifies for the COVID Vaccine Under CDC Guidelines

Overview of Randomized Trials of Antithrombotic Therapy for COVID-19 Patients.

VIDEO: Antithrombotic Prophylaxis in COVID-19 Patients —Interview with Behnood Bikdeli M.D.

Cardiology related COVID news and video

 

Related Content

One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infarction (STEMI), according to the latest, comprehensive data from The North American COVID-19 Myocardial Infarction (NACMI) Registry. The data was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions. The study showed there was an alarming one-in-three patients dying with STEMI and COVID, compared to 4-in-100 #SCAI2021

The key slide from the SCAI 2021 NACMI late-breaking presentation showing the very high adverse rates for COVID STEMI heart attack patients (red) as compared to pre-pandemic STEMI patient controls (green).

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
May 3, 2021 – One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infar
COVID-19 disrupted all aspects of science and medicine and unmasked striking disparities and opportunities for transformation. Coronavirus impact this past year is expected to result in a massive rise in new cases of chronic health conditions, including cardiolvascular disease and heart failure.
News | Coronavirus (COVID-19) | April 07, 2021
April 6, 2021 — A tsunami of chronic health conditions as a result of the...
MRI scan of a damaged heart. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Image courtesy of European Heart Journal #COVID #COVID19

MRI scan of a damaged heart. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Image courtesy of European Heart Journal

News | Coronavirus (COVID-19) | March 17, 2021
March 17, 2021 — Around 50% of patients who have been hospitalized with severe...
A study from Washington University School of Medicine in St. Louis provides evidence that the coronavirus can invade and replicate inside heart muscle cells, causing cell death and interfering with heart muscle contraction. The image of engineered heart tissue shows human heart muscle cells (red) infected with COVID-19 (SARS-CoV-2) (green). Image by Lina Greenberg.

A study from Washington University School of Medicine in St. Louis provides evidence that the coronavirus can invade and replicate inside heart muscle cells, causing cell death and interfering with heart muscle contraction. The image of engineered heart tissue shows human heart muscle cells (red) infected with COVID-19 (SARS-CoV-2) (green). Image by Lina Greenberg.

Feature | Coronavirus (COVID-19) | March 12, 2021
March 12, 2021 — Since early in the pandemic,...
Interactions between capillary function, inflammation, hypoxia, and neurotransmission. The expression of ACE2 and other SARS‐CoV‐2 entry factors on parenchymal cells and observations of infected cells in biopsy material hold important clues to understand COVID‐19‐related organ damage. COVID-19 Blood Vessel Damage May Cause Brain Fog and Other Long-hauler Symptoms

Interactions between capillary function, inflammation, hypoxia, and neurotransmission. The expression of ACE2 and other SARS‐CoV‐2 entry factors on parenchymal cells and observations of infected cells in biopsy material hold important clues to understand COVID‐19‐related organ damage. Find more figures and read the full study.

News | Coronavirus (COVID-19) | March 12, 2021
March 12, 2021 — A new review suggests that blood vessel damage and impaired oxygen delivery related to...
FDA Clears Third COVID-19 Vaccine From Janssen, Johnson and Johnson, J&J
News | Coronavirus (COVID-19) | March 01, 2021
March 1, 2021 — The U.S.
UK hospU.K. hospital admissions for heart attacks and heart failure were reduced by more than 50 percent in the spring of 2020 and by more than a third in the second wave of COVID-19 as people fear going to hospitals and ignore serious symptoms.ital admissions for heart attacks and heart failure have been reduced by COVID-19 as people fear going to hospitals. Getty Images #COVIDUK #COVID19

U.K. hospital admissions for heart attacks and heart failure were reduced by more than 50 percent in the spring of 2020 and by more than a third in the second wave of COVID-19 as people fear going to hospitals and ignore serious symptoms. Getty Images

News | Coronavirus (COVID-19) | February 24, 2021
February 24, 2021 — A study of admissions for acute myocardial infarction (AMI) and...
Vaccinating patients against the flu can go a long way to helping cardiology patients stay healthy and out of the hospital during the COVID-19 pandemic, freeing up beds for COVID patients. Left photo, Getty Images, right image of COVID-19 virus from the NIH.

Vaccinating patients against the flu can go a long way to helping cardiology patients stay healthy and out of the hospital during the COVID-19 pandemic, freeing up beds for COVID patients. Left photo, Getty Images, right image of COVID-19 virus from the NIH.

Feature | Coronavirus (COVID-19) | February 23, 2021 | By William Schaffner, M.D., and Allen J. Taylor, M.D.
While influenza (flu) is unpredictable, the 2020-2021 influenza season may present an unprecedented dual threat: co-c